RxDoctor Payments Data

Sheba Mohsin, MD

Family Medicine · Williamsburg, VANPI 1225290679

Payments from drug & device makers

$1,118in general payments, 2019–2025

Across 60 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$246
  • Amgen$179
  • Pfizer$106
  • Novo Nordisk$103
  • Lilly USA, LLC$87
  • AbbVie$66
  • plus $330 from 10 others

What the payments were for

  • Food & beverage$1,118100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,118 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$214,325
Medicare patients
353
Services billed
4,994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate23$22,662
XareltoRivaroxaban11$18,404
TrulicityDulaglutide14$18,258
MounjaroTirzepatide11$11,533
JardianceEmpagliflozin13$7,800
Spiriva HandihalerTiotropium Bromide11$6,430
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$4,266
Omeprazole246$2,454
Levothyroxine Sodium209$2,013
Albuterol Sulfate HfaAlbuterol Sulfate74$1,991
Atorvastatin Calcium241$1,962
Losartan Potassium214$1,920
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,846
Simvastatin200$1,437
Bupropion XlBupropion Hcl73$1,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$87$29,79125 claims
MerckJanuvia$47$22,66223 claims
Johnson & JohnsonXarelto$59$18,40411 claims
Boehringer IngelheimJardiance$17$7,80013 claims
AbbVieSynthroid$66$74039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →